The selective delivery of (10)B into the tumor tissue remains to be further improved for successful and reliable Boron Neutron Capture Therapy applications. Magnetic Drug Targeting using intraarterially administered superparamagnetic nanoparticles and external magnetic fields already exhibited convincing results in terms of highly efficient and selective drug deposition. Using the same technique for the targeted (10)B delivery is a promising new approach. Here, systematic irradiation experiments of phantom cubes containing different concentrations of boron and nanoparticles as well as varying three-dimensional arrangements have been performed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2015.07.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Curvature Memory in Electrically Stimulated Lipid Membranes.
Langmuir
January 2025
Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, United States.
We demonstrate, using non-equilibrium molecular dynamics simulations, that lipid membrane capacitance varies with surface charge accumulation linked to membrane shape and curvature changes. Specifically, we show that lipid membranes exhibit a hysteretic response when exposed to oscillatory electric fields. The electromechanical coupling in these membranes leads to hysteretic buckling, in which the membrane can spontaneously buckle in one of two distinct directions along the electric field, even for the same ionic charge accumulation at the water-membrane interface.
View Article and Find Full Text PDFTargeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis.
Pharmaceutics
January 2025
Key Laboratory of Molecular Biophysics, Institute of Biophysics, School of Health Sciences & Biomedical Engineering, Hebei University of Technology, Tianjin 300401, China.
Brain diseases pose significant treatment challenges due to the restrictive nature of the blood-brain barrier (BBB). Recent advances in targeting macromolecules offer promising avenues for overcoming these obstacles through receptor-mediated transcytosis (RMT). We summarize the current progress in targeting brain drug delivery with macromolecules for brain diseases.
View Article and Find Full Text PDFHeterogeneous head phantom for validating treatment planning system in boron neutron capture therapy.
Appl Radiat Isot
January 2025
Institute of Nuclear Engineering and Science, National Tsing Hua University, 101, Sec. 2, Kuang-Fu Road, Hsinchu, 30013, Taiwan; Nuclear Science and Technology Development Center, National Tsing Hua University, 101, Sec. 2, Kuang-Fu Road, Hsinchu, 30013, Taiwan. Electronic address:
In clinical boron neutron capture therapy (BNCT), the distribution of dose to a heterogeneous medium that is predicted by a treatment planning system (TPS) should be experimentally validated. A head phantom specifically developed for this purpose is described and demonstrated herein. The cylindrical phantom exhibits distinct regions made from four materials (polymethyl methacrylate, calcium phosphate, air, and boric acid) to approximate a head structure with explicitly defined skin, skull, and brain tissue with a cavity and tumor within.
View Article and Find Full Text PDFExpression rate of LAT1 in high-grade parotid gland carcinoma and potential of BNCT as a treatment option for recurrent parotid gland carcinoma.
Appl Radiat Isot
January 2025
Department of Otolaryngology Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Purpose: Boron neutron capture therapy (BNCT) perform as a treatment option for locally advanced or recurrent unresectable head and neck cancers since June 2020 in Japan. The effect of BNCT on parotid carcinoma, which presents a variety of histologic types, remains unclear. The object of this study was to investigate the antitumor efficacy of BNCT against parotid gland carcinoma by focusing on LAT1, which is involved in the uptake of L-BPA, the boron compound used in BNCT.
View Article and Find Full Text PDFA 77-year-old man was referred to our department because of macrohematuria, oliguria, and a serum creatinine level of 2.47 mg/dL during boron neutron capture therapy (BNCT) for oropharyngeal cancer. At baseline, his creatinine level had been 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!